APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

FAP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global FAP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173990760329 December 2025188 pages

Choose your research edition.

Industry ResearchFAP Inhibitor Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal FAP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal FAP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FAP Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal FAP Inhibitor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global FAP Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of FAP Inhibitor include SOFIE, Ferronova, GE HealthCare, Isotopia, Lantheus, Bayer and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FAP Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FAP Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FAP Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FAP Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

FAP Inhibitor Segment by Company

SOFIE

Ferronova

GE HealthCare

Isotopia

Lantheus

Bayer

Novartis AG

FAP Inhibitor Segment by Type

Ga-labeled

F-labeled

Other

FAP Inhibitor Segment by Application

Tumor Diagnosis

Tumor Treatment

Others

FAP Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FAP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FAP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FAP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FAP Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of FAP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of FAP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of FAP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. FAP Inhibitor Industry Trends Table 2. FAP Inhibitor Industry Drivers Table 3. FAP Inhibitor Industry Opportunities and Challenges Table 4. FAP Inhibitor Industry Restraints Table 5. Global FAP Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global FAP Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global FAP Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global FAP Inhibitor Sales Market Share by Manufacturers Table 9. Global FAP Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global FAP Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global FAP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global FAP Inhibitor Manufacturers, Product Type & Application Table 13. Global FAP Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global FAP Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ga-labeled Table 17. Major Manufacturers of F-labeled Table 18. Major Manufacturers of Other Table 19. Global FAP Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global FAP Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. Global FAP Inhibitor Sales by Type (2027-2032) & (K Units) Table 22. Global FAP Inhibitor Sales Market Share by Type (2021-2026) Table 23. Global FAP Inhibitor Sales Market Share by Type (2027-2032) Table 24. Global FAP Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global FAP Inhibitor Revenue by Type (2021-2026) & (K Units) Table 26. Global FAP Inhibitor Revenue by Type (2027-2032) & (K Units) Table 27. Global FAP Inhibitor Revenue Market Share by Type (2021-2026) Table 28. Global FAP Inhibitor Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Tumor Diagnosis Table 30. Major Manufacturers of Tumor Treatment Table 31. Major Manufacturers of Others Table 32. Global FAP Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global FAP Inhibitor Sales by Application (2021-2026) & (K Units) Table 34. Global FAP Inhibitor Sales by Application (2027-2032) & (K Units) Table 35. Global FAP Inhibitor Sales Market Share by Application (2021-2026) Table 36. Global FAP Inhibitor Sales Market Share by Application (2027-2032) Table 37. Global FAP Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global FAP Inhibitor Revenue by Application (2021-2026) & (K Units) Table 39. Global FAP Inhibitor Revenue by Application (2027-2032) & (K Units) Table 40. Global FAP Inhibitor Revenue Market Share by Application (2021-2026) Table 41. Global FAP Inhibitor Revenue Market Share by Application (2027-2032) Table 42. Global FAP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global FAP Inhibitor Sales by Region (2021-2026) & (K Units) Table 44. Global FAP Inhibitor Sales Market Share by Region (2021-2026) Table 45. Global FAP Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global FAP Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 47. North America FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America FAP Inhibitor Sales by Country (2021-2026) & (K Units) Table 49. North America FAP Inhibitor Sales by Country (2027-2032) & (K Units) Table 50. Europe FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe FAP Inhibitor Sales by Country (2021-2026) & (K Units) Table 52. Europe FAP Inhibitor Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific FAP Inhibitor Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific FAP Inhibitor Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa FAP Inhibitor Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa FAP Inhibitor Sales by Country (2027-2032) & (K Units) Table 59. Global FAP Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global FAP Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 61. Global FAP Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 62. Global FAP Inhibitor Revenue Market Share by Region (2021-2026) Table 63. Global FAP Inhibitor Revenue Market Share by Region (2027-2032) Table 64. SOFIE Company Information Table 65. SOFIE Business Overview Table 66. SOFIE FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. SOFIE FAP Inhibitor Product Portfolio Table 68. SOFIE Recent Development Table 69. Ferronova Company Information Table 70. Ferronova Business Overview Table 71. Ferronova FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Ferronova FAP Inhibitor Product Portfolio Table 73. Ferronova Recent Development Table 74. GE HealthCare Company Information Table 75. GE HealthCare Business Overview Table 76. GE HealthCare FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. GE HealthCare FAP Inhibitor Product Portfolio Table 78. GE HealthCare Recent Development Table 79. Isotopia Company Information Table 80. Isotopia Business Overview Table 81. Isotopia FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Isotopia FAP Inhibitor Product Portfolio Table 83. Isotopia Recent Development Table 84. Lantheus Company Information Table 85. Lantheus Business Overview Table 86. Lantheus FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Lantheus FAP Inhibitor Product Portfolio Table 88. Lantheus Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bayer FAP Inhibitor Product Portfolio Table 93. Bayer Recent Development Table 94. Novartis AG Company Information Table 95. Novartis AG Business Overview Table 96. Novartis AG FAP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novartis AG FAP Inhibitor Product Portfolio Table 98. Novartis AG Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. FAP Inhibitor Distributors List Table 102. FAP Inhibitor Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. FAP Inhibitor Product Image Figure 2. Global FAP Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FAP Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global FAP Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global FAP Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 FAP Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ga-labeled Image Figure 9. F-labeled Image Figure 10. Other Image Figure 11. Global FAP Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global FAP Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global FAP Inhibitor Sales Market Share by Type (2021-2032) Figure 14. Global FAP Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global FAP Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global FAP Inhibitor Revenue Market Share by Type (2021-2032) Figure 17. Tumor Diagnosis Image Figure 18. Tumor Treatment Image Figure 19. Others Image Figure 20. Global FAP Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global FAP Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global FAP Inhibitor Sales Market Share by Application (2021-2032) Figure 23. Global FAP Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global FAP Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global FAP Inhibitor Revenue Market Share by Application (2021-2032) Figure 26. North America FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America FAP Inhibitor Sales Market Share by Country (2021-2032) Figure 28. U.S. FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe FAP Inhibitor Sales Market Share by Country (2021-2032) Figure 33. Germany FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific FAP Inhibitor Sales Market Share by Country (2021-2032) Figure 40. China FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa FAP Inhibitor Sales Market Share by Country (2021-2032) Figure 48. Brazil FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile FAP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global FAP Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global FAP Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America FAP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 59. North America FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe FAP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. Europe FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific FAP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa FAP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. FAP Inhibitor Value Chain Figure 67. Manufacturing Cost Structure Figure 68. FAP Inhibitor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Ga-labeled
  • F-labeled
  • Other
Applications
  • Tumor Diagnosis
  • Tumor Treatment
  • Others
Companies covered
  • SOFIE
  • Ferronova
  • GE HealthCare
  • Isotopia
  • Lantheus
  • Bayer
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global FAP Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global FAP Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global FAP Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global FAP Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global FAP Inhibitor Market Dynamics
  1. 2.1 FAP Inhibitor Industry Trends
  2. 2.2 FAP Inhibitor Industry Drivers
  3. 2.3 FAP Inhibitor Industry Opportunities and Challenges
  4. 2.4 FAP Inhibitor Industry Restraints
3 FAP Inhibitor Market by Manufacturers
  1. 3.1 Global FAP Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global FAP Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global FAP Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global FAP Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global FAP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global FAP Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global FAP Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global FAP Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 FAP Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 FAP Inhibitor Tier 1, Tier 2, and Tier 3
4 FAP Inhibitor Market by Type
  1. 4.1 FAP Inhibitor Type Introduction
  2. 4.1.1 Ga-labeled
  3. 4.1.2 F-labeled
  4. 4.1.3 Other
  5. 4.2 Global FAP Inhibitor Sales by Type
  6. 4.2.1 Global FAP Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global FAP Inhibitor Sales by Type (2021-2032)
  8. 4.2.3 Global FAP Inhibitor Sales Market Share by Type (2021-2032)
  9. 4.3 Global FAP Inhibitor Revenue by Type
  10. 4.3.1 Global FAP Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global FAP Inhibitor Revenue by Type (2021-2032)
  12. 4.3.3 Global FAP Inhibitor Revenue Market Share by Type (2021-2032)
5 FAP Inhibitor Market by Application
  1. 5.1 FAP Inhibitor Application Introduction
  2. 5.1.1 Tumor Diagnosis
  3. 5.1.2 Tumor Treatment
  4. 5.1.3 Others
  5. 5.2 Global FAP Inhibitor Sales by Application
  6. 5.2.1 Global FAP Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FAP Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global FAP Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global FAP Inhibitor Revenue by Application
  10. 5.3.1 Global FAP Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FAP Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global FAP Inhibitor Revenue Market Share by Application (2021-2032)
6 Global FAP Inhibitor Sales by Region
  1. 6.1 Global FAP Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FAP Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global FAP Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global FAP Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America FAP Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe FAP Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific FAP Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa FAP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa FAP Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global FAP Inhibitor Revenue by Region
  1. 7.1 Global FAP Inhibitor Revenue by Region
  2. 7.1.1 Global FAP Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global FAP Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global FAP Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global FAP Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America FAP Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe FAP Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific FAP Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa FAP Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa FAP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 SOFIE
  2. 8.1.1 SOFIE Company Information
  3. 8.1.2 SOFIE Business Overview
  4. 8.1.3 SOFIE FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 SOFIE FAP Inhibitor Product Portfolio
  6. 8.1.5 SOFIE Recent Developments
  7. 8.2 Ferronova
  8. 8.2.1 Ferronova Company Information
  9. 8.2.2 Ferronova Business Overview
  10. 8.2.3 Ferronova FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferronova FAP Inhibitor Product Portfolio
  12. 8.2.5 Ferronova Recent Developments
  13. 8.3 GE HealthCare
  14. 8.3.1 GE HealthCare Company Information
  15. 8.3.2 GE HealthCare Business Overview
  16. 8.3.3 GE HealthCare FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GE HealthCare FAP Inhibitor Product Portfolio
  18. 8.3.5 GE HealthCare Recent Developments
  19. 8.4 Isotopia
  20. 8.4.1 Isotopia Company Information
  21. 8.4.2 Isotopia Business Overview
  22. 8.4.3 Isotopia FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Isotopia FAP Inhibitor Product Portfolio
  24. 8.4.5 Isotopia Recent Developments
  25. 8.5 Lantheus
  26. 8.5.1 Lantheus Company Information
  27. 8.5.2 Lantheus Business Overview
  28. 8.5.3 Lantheus FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus FAP Inhibitor Product Portfolio
  30. 8.5.5 Lantheus Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer FAP Inhibitor Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG FAP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG FAP Inhibitor Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FAP Inhibitor Value Chain Analysis
  2. 9.1.1 FAP Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FAP Inhibitor Production Mode & Process
  6. 9.2 FAP Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FAP Inhibitor Distributors
  9. 9.2.3 FAP Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst